Literature DB >> 23620071

Intramedullary spinal cord metastases: MRI and relevant clinical features from a 13-year institutional case series.

J B Rykken1, F E Diehn, C H Hunt, K M Schwartz, L J Eckel, C P Wood, T J Kaufmann, R K Lingineni, R E Carter, J T Wald.   

Abstract

BACKGROUND AND
PURPOSE: Because intramedullary spinal cord metastasis is often a difficult diagnosis to make, our purpose was to perform a systematic review of the MR imaging and relevant baseline clinical features of intramedullary spinal cord metastases in a large series.
MATERIALS AND METHODS: Consecutive patients with intramedullary spinal cord metastasis with available pretreatment digital MR imaging examinations were identified. The MR imaging examination(s) for each patient was reviewed by 2 neuroradiologists for various imaging characteristics. Relevant clinical data were obtained.
RESULTS: Forty-nine patients had 70 intramedullary spinal cord metastases, with 10 (20%) having multiple intramedullary spinal cord metastases; 8% (4/49) were asymptomatic. Primary tumor diagnosis was preceded by intramedullary spinal cord metastasis presentation in 20% (10/49) and by intramedullary spinal cord metastasis diagnosis in 10% (5/49); 98% (63/64) of intramedullary spinal cord metastases enhanced. Cord edema was extensive: mean, 4.5 segments, 3.6-fold larger than enhancing lesion, and ≥3 segments in 54% (37/69). Intratumoral cystic change was seen in 3% (2/70) and hemorrhage in 1% (1/70); 59% (29/49) of reference MR imaging examinations displayed other CNS or spinal (non-spinal cord) metastases, and 59% (29/49) exhibited the primary tumor/non-CNS metastases, with 88% (43/49) displaying ≥1 finding and 31% (15/49) displaying both findings. Patients with solitary intramedullary spinal cord metastasis were less likely than those with multiple intramedullary spinal cord metastases to have other CNS or spinal (non-spinal cord) metastases on the reference MR imaging (20/39 [51%] versus 9/10 [90%], respectively; P = .0263).
CONCLUSIONS: Lack of known primary malignancy or spinal cord symptoms should not discourage consideration of intramedullary spinal cord metastasis. Enhancement and extensive edema for lesion size (often ≥3 segments) are typical for intramedullary spinal cord metastasis. Presence of cystic change/hemorrhage makes intramedullary spinal cord metastasis unlikely. Evidence for other CNS or spinal (non-spinal cord) metastases and the primary tumor/non-CNS metastases are common. The prevalence of other CNS or spinal (non-spinal cord) metastases in those with multiple intramedullary spinal cord metastases is especially high.

Entities:  

Mesh:

Year:  2013        PMID: 23620071      PMCID: PMC7965414          DOI: 10.3174/ajnr.A3526

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  16 in total

1.  Intramedullary spinal cord metastases in breast cancer are associated with improved longer-term systemic control.

Authors:  Adrian Zebrowski; Louise Wilson; Adrian Lim; Justin Stebbing; Jonathan Krell
Journal:  Future Oncol       Date:  2010-09       Impact factor: 3.404

Review 2.  Metastasis to nervous system: spinal epidural and intramedullary metastases.

Authors:  Melike Mut; David Schiff; Mark E Shaffrey
Journal:  J Neurooncol       Date:  2005-10       Impact factor: 4.130

Review 3.  Intramedullary spinal cord metastases of malignant melanoma: an autopsy case report and review of the literature.

Authors:  T Ishii; T Terao; K Komine; T Abe
Journal:  Clin Neuropathol       Date:  2010 Sep-Oct       Impact factor: 1.368

Review 4.  Neoplasms of the spinal cord and filum terminale: radiologic-pathologic correlation.

Authors:  K K Koeller; R S Rosenblum; A L Morrison
Journal:  Radiographics       Date:  2000 Nov-Dec       Impact factor: 5.333

5.  Intramedullary spinal cord metastases: a 20-year institutional experience with a comprehensive literature review.

Authors:  Wen-Shan Sung; Mei-Jo Sung; Jon Ho Chan; Benjamin Manion; Jeeuk Song; Arvind Dubey; Albert Erasmus; Andrew Hunn
Journal:  World Neurosurg       Date:  2012-04-06       Impact factor: 2.104

6.  Rim and flame signs: postgadolinium MRI findings specific for non-CNS intramedullary spinal cord metastases.

Authors:  J B Rykken; F E Diehn; C H Hunt; L J Eckel; K M Schwartz; T J Kaufmann; J T Wald; C Giannini; C P Wood
Journal:  AJNR Am J Neuroradiol       Date:  2012-10-18       Impact factor: 3.825

7.  Intramedullary spinal cord metastases: clinical features and treatment outcome.

Authors:  D Schiff; B P O'Neill
Journal:  Neurology       Date:  1996-10       Impact factor: 9.910

8.  Retrospective study of 19 patients with intramedullary spinal cord metastasis.

Authors:  Phong Dam-Hieu; Romuald Seizeur; Jean-François Mineo; Jean-Philippe Metges; Philippe Meriot; Hélène Simon
Journal:  Clin Neurol Neurosurg       Date:  2008-10-19       Impact factor: 1.876

9.  Intramedullary spinal cord metastasis: a clinical and imaging study of seven patients.

Authors:  Masahiko Watanabe; Takeshi Nomura; Eiren Toh; Masato Sato; Joji Mochida
Journal:  J Spinal Disord Tech       Date:  2006-02

10.  Intramedullary spinal cord metastasis. A clinicopathological study of 13 cases.

Authors:  D A Costigan; M D Winkelman
Journal:  J Neurosurg       Date:  1985-02       Impact factor: 5.115

View more
  14 in total

1.  Intramedullary spinal cord metastases: prognostic value of MRI and clinical features from a 13-year institutional case series.

Authors:  F E Diehn; J B Rykken; J T Wald; C P Wood; L J Eckel; C H Hunt; K M Schwartz; R K Lingineni; R E Carter; T J Kaufmann
Journal:  AJNR Am J Neuroradiol       Date:  2014-11-13       Impact factor: 3.825

2.  Clinical Reasoning: an unusual cause of transverse myelitis?

Authors:  Pavan Bhargava; Rodger J Elble
Journal:  Neurology       Date:  2014-02-11       Impact factor: 9.910

Review 3.  Imaging of metastases from breast cancer to uncommon sites: a pictorial review.

Authors:  Masafumi Toguchi; Mitsuru Matsuki; Isao Numoto; Masakatsu Tsurusaki; Izumi Imaoka; Kazunari Ishii; Rikiya Yamashita; Yuki Inada; Shuichi Monzawa; Hisato Kobayashi; Takamichi Murakami
Journal:  Jpn J Radiol       Date:  2016-04-08       Impact factor: 2.374

4.  The Central Dot Sign : A Specific Post-gadolinium Enhancement Feature of Intramedullary Spinal Cord Metastases.

Authors:  Ajay A Madhavan; Felix E Diehn; Jeffrey B Rykken; John T Wald; Chris P Wood; Kara M Schwartz; Timothy J Kaufmann; Christopher H Hunt; Dong Kun Kim; Laurence J Eckel
Journal:  Clin Neuroradiol       Date:  2020-05-07       Impact factor: 3.649

5.  Intramedullary spinal cord metastases: visibility on PET and correlation with MRI features.

Authors:  P M Mostardi; F E Diehn; J B Rykken; L J Eckel; K M Schwartz; T J Kaufmann; C P Wood; J T Wald; C H Hunt
Journal:  AJNR Am J Neuroradiol       Date:  2013-07-25       Impact factor: 3.825

Review 6.  [18F]FDG-PET Evaluation of Spinal Pathology in Patients in Oncology: Pearls and Pitfalls for the Neuroradiologist.

Authors:  P Y Patel; I Dalal; B Griffith
Journal:  AJNR Am J Neuroradiol       Date:  2021-10-28       Impact factor: 3.825

Review 7.  Metastatic Complications of Cancer Involving the Central and Peripheral Nervous Systems.

Authors:  Joe S Mendez; Lisa M DeAngelis
Journal:  Neurol Clin       Date:  2018-06-15       Impact factor: 3.806

8.  Longitudinally extensive transverse myelitis as presenting manifestation of small cell carcinoma lung.

Authors:  Rajendra Singh Jain; Pankaj Kumar Gupta; Rakesh Agrawal; Shankar Tejwani; Sunil Kumar
Journal:  Oxf Med Case Reports       Date:  2015-02-26

9.  [Intramedullary metastasis of lung adenocarcinoma: about a case].

Authors:  Hicham Naji-Amrani; Hicham Janah; Fatimazahra Sqalli; Hicham Souhi; Adil Zegmout; Hanane Elouazzani; Ismail Abderrahmani Rhorfi; Ahmed Abid
Journal:  Pan Afr Med J       Date:  2015-01-14

Review 10.  Intramedullary Spinal Cord Tumors: Part I-Epidemiology, Pathophysiology, and Diagnosis.

Authors:  Dino Samartzis; Christopher C Gillis; Patrick Shih; John E O'Toole; Richard G Fessler
Journal:  Global Spine J       Date:  2015-03-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.